Physician profile
James K Ahern
NPI 1356385868
$6,607.12
in general payments reported to CMS, 2019-2025
50 companies · $1,011 in 2025
The $1,011 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $982 · 2020: $878 · 2021: $925 · 2022: $895 · 2023: $1,069 · 2024: $846 · 2025: $1,011.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,900 · Education: $26.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,899.96 |
| Education | $26.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $951.28 | 2019-2025 | Vraylar, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $900.36 | 2019-2025 | Breztri, Farxiga |
| Pfizer INC. | $817.77 | 2019-2025 | |
| Glaxosmithkline, LLC. | $537.57 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Amneal Pharmaceuticals LLC | $376.58 | 2019-2025 | Unithroid |
| Merck Sharp & Dohme LLC | $289.88 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $265.42 | 2022-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $226.00 | 2019-2022 | |
| Astellas Pharma US INC | $195.70 | 2019-2023 | Veozah |
| Eisai INC. | $164.26 | 2020-2024 | |
| Novo Nordisk INC | $154.94 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.07 | 2019-2024 | Ofev |
| Sumitomo Pharma America, INC. | $103.66 | 2023-2024 | Gemtesa |
| Amarin Pharma, INC. | $99.77 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $96.29 | 2021-2022 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Ahern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.